Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

• Status: Terminated
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive heart failure

• History of Stage C-D heart failure with EF ≤ 40% during the course of the disease

• Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant)

• Age > 18 yrs

Exclusion Criteria:

• Cardiomyopathy due to one of the following:

• Ischemic heart disease

• Primary valvular lesion

• Hypertrophic cardiomyopathy

• Cardiac resynchronization within the last 3 months

• Transaminase values > 2.5 x upper limit of normal or history of liver disease

• Diagnosis of diabetes mellitus by:

• Diabetes previously diagnosed per patient history

• 2 or more fasting glucose values > 125 mg/dl

• Current NYHA class III or IV heart failure

• Serum creatinine > 1.6 mg/dl

• History of heart transplantation

• Pregnancy or active breast feeding

• Hospitalization for decompensated heart failure within 30 days prior to enrollment.